Imprimir Resumo


Congresso Brasileiro de Microbiologia 2023
Resumo: 1230-1

1230-1

Microbiological and metabolomic benefits of the reconstruction of pasteurized donor's milk microbiota with mother's own milk of premature newborns: results of a clinical trial

Autores:
Lucas de Figueiredo Soveral (UFSC - Universidade Federal de Santa Catarina) ; Thaise Cristina Brancher Soncini (MCD - Maternidade Carmela Dutra) ; Isis Maia Apolinário de Mello (UFSC - Universidade Federal de Santa Catarina) ; Izadora Borgmann Frizzo (UFSC - Universidade Federal de Santa Catarina) ; Lívia Budziarek Eslabão (UFSC - Universidade Federal de Santa Catarina) ; Dany Mesa (IPPP - Instituto de Pesquisa Pelé Pequeno Príncipe) ; Thaís Cristine Marques Sincero (UFSC - Universidade Federal de Santa Catarina) ; Jussara Kasuko Palmeiro (UFSC - Universidade Federal de Santa Catarina) ; Oscar Bruna-romero (UFSC - Universidade Federal de Santa Catarina) ; Maria Marlene de Souza Pires (UFSC - Universidade Federal de Santa Catarina) ; Carlos Arterio Sorgi (USP - Universidade de São Paulo) ; Carlos Rodrigo Zárate-bladés (UFSC - Universidade Federal de Santa Catarina)

Resumo:
Human milk and its associated commensal microbiota are extremely important for neonates, especially premature newborns (PNs). Pasteurized donor's milk (PDM) is the best option if mother's own milk (MOM) is not available, which is a common problem in preterm pregnancies. However, pasteurization strongly affects the microbiota and consequently, with negative impacts on PDM benefits. To address this problem, we conducted a randomized clinical study (ReBEC:RBR-729kr8x) exploring the feasibility of reconstructing the microbiome of PDM by supplementing it with 10% premature MOM followed by incubation at 37༠C for 4 h. Eighty PNs (<32 weeks) and their mothers were enrolled. PNs received either PDM or RM. The PN's fecal microbiota and also the microbiota of PDM, MOM and RM were determined by 16S rDNA sequencing. In addition, untargeted liquid chromatography-mass spectrometry (LC-MS) was used for metabolomic analysis. Feature extraction and statistical analysis were performed in R and Metaboanalyst®. Genera and metabolite annotation were done using RDP, Silva, Lipid Maps, and Human Metabolome data banks. The microbiota analysis of the milk showed that the three groups (PDM, MOM and RM) shared the same 10 most abundant genera, including Acinetobacter, Enterobacter, Klebsiella, Novosphingobium, Pantoea, Pseudomonas, Sphingomonas, Staphylococcus, Stenotrophomonas, and Streptococcus. Interestingly, the microbiota analysis of individualized milk samples showed that most of RM samples exhibited a microbiota composition profile more closely to MOM's microbiota rather than to PDM after 4-hour incubation (Figure 1). Moreover, the fecal microbiota of PNs that received RM exhibited significantly increased levels of Acinetobacter, Enterobacter, Novosphingobium, and Veillonella genera compared to PDM controls. Conversely, Clostridium, Enterococcus, Klebsiella, Kluyvera, Pseudescherichia, and Serratia were more abundant in the PDM group compared to RM (Figure 2). These findings indicate that the microbiota reconstruction of PDM with MOM induced alterations in the fecal microbiota composition of preterm infants, which could potentially influence their gut health and immune development. In addition, the metabolomic analysis of milk samples showed significant differences between PDM and RM (Figure 3). Specifically, RM samples exhibited an increased area ratio (AR) of oxidized lysophospholipids (lysoPLs) (mean: 0.05696) compared to PDM (0.03980). Sphingomyelin species showed a significantly higher AR in RM (mean: 0.2436) than in PDM (0.1455), along with higher prostaglandin A1 levels in RM (mean: 1.608) compared to PDM (0.9654) (p: <0.005). Additionally, an increased AR of Coenzyme A was observed in RM (mean: 0.3224) compared to PDM (0.1055). Lastly, the AR of tryptophan and its metabolite indoleacrylic acid was significantly higher in RM (mean: 0.08042 and 0.1965, respectively) versus in PDM (mean: 0.03436 and 0.08771) (p: <0.005). Although further clinical analysis is crucial to fully determine the practical benefits of these findings for PNs, the results presented here support for a feasible insight that highly improves the quality of PDM in a simple and fast manner that could be easily adopted in neonate care units.

Palavras-chave:
 PRETERM, IMMUNITY, MICROBIOME, METABOLITES, CLINICAL STUDY


Agência de fomento:
FAPESC/TR2021000506